文献速递淋巴瘤

预测滤泡性淋巴瘤患者早期事件的基因表达特征模型的开发与验证

Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

FL24Cx是基于45个靶基因表达谱(GEP)的算法,用265份福尔马林固定石蜡包埋组织样本开发并训练,用于在诊断时预测患者24个月内是否发生事件。该5因素逻辑回归模型在SWOG S0016 3期临床试验的232例回顾性评估队列中独立验证,高危组相对低危组24个月内事件相对风险为2.2(95%CI 1.41-3.51)。

要点

  • FL24Cx为基于45个靶基因GEP的5因素逻辑回归模型,用于诊断时预测24个月内事件。
  • 验证队列中低危组169例,24个月内事件29例(17.2%);高危组63例,事件24例(38.1%)。
  • 高危组相对低危组24个月内事件相对风险2.2(95%CI 1.41-3.51)。

核心结论

  • FL24Cx这种经临床实验室严格验证且周转时间具有临床相关性的前置GEP生物标志物,可识别高危早期事件患者并引导其入组临床试验。

研究设计与样本

  • FL24Cx算法基于45个靶基因表达谱(GEP)检测,使用265份福尔马林固定石蜡包埋组织样本在可靠平台上开发并训练。
  • 锁定后的5因素逻辑回归FL24Cx模型在SWOG癌症研究网络S0016 3期临床试验2个免疫化疗治疗组的232例回顾性评估队列中独立验证。

主要发现

  • 建模确认并依赖于既往报道的免疫应答(IR)基因表达特征IR1与IR2之间的协同作用。
  • 验证队列中FL24Cx将169例归为低危组,24个月前事件29例(17.2%);63例归为高危组,24个月前事件24例(38.1%)。
  • 入组后24个月内发生事件的相对风险,高危组相对低危组为2.2(95%CI 1.41-3.51)。

关键数值与推荐

  • FL24Cx为5因素逻辑回归模型,基于45个靶基因GEP检测,预测诊断时24个月内事件。
  • 验证队列中低危组169例,24个月内事件29例(17.2%);高危组63例,事件24例(38.1%)。
  • 高危组相对低危组24个月内事件相对风险2.2(95%CI 1.41-3.51)。

临床怎么用

  • 原文结论指出,FL24Cx这种前置GEP生物标志物可识别高危早期事件患者并引导其入组临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based on a 45-target gene expression profiling (GEP) assay, which was developed and trained using 265 formalin-fixed, paraffin-embedded tissue samples on a reliable platform to predict, at the time of diagnosis, whether a patient will experience an event within 24 months. The modeling also confirmed and relied upon previously reported synergy between immune response (IR) gene expression signatures IR1 and IR2. Once locked, the 5-factor logistic regression FL24Cx model was independently validated in a retrospectively assessed cohort of 232 patients from 2 immunochemotherapy-treated arms of SWOG Cancer Research Network S0016 phase 3 clinical trial, in which it assigned 169 patients to the low-risk group with 29 events before 24 months (17.2%) and 63 patients to the high-risk group with 24 events before 24 months (38.1%). The relative risk of an event within 24 months after registration among patients who were classified into the high-risk group relative to patients who were classified into the low-risk group was 2.2 (95% confidence interval, 1.41 to 3.51). An up-front GEP biomarker, such as the FL24Cx, rigorously validated in a clinical laboratory and with a clinically relevant turnaround time, could identify and steer enrollment of patients at high risk for early events in clinical trials, thus enabling timely interpretation of such trials and increasing the pace of innovation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ramsower CA, Wright G, Li H, et al. Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma. Blood Adv. 2025. PMID: 40966421. doi:10.1182/bloodadvances.2025016827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。